Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic-Reference-Cited by-同舟云学术

Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic

Published:2021-11-11 Issue:2 Volume:40 Page:115-123
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Javadinia Seyed Alireza¹^ORCID,Ariamanesh Mona²^ORCID,Nabavifard Maryam¹^ORCID,Porouhan Pejman³^ORCID,PeyroShabany Babak⁴^ORCID,Fazilat-Panah Danial⁵^ORCID,Hatami Farbod⁶^ORCID,Ghasemi Ahmad⁷^ORCID,Lyman Gary H.⁸^ORCID,Welsh James S.⁹^ORCID,Ashkar Tizabi Somayeh¹⁰,Dehghani Mansoureh¹¹^ORCID

Affiliation:

1. Clinical Research Development Unit, Hospital Research Development Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran

2. Anatomical and Clinical Pathologist, Department of Pathology, Neyshabur University of Medical Sciences, Neyshabur, Iran

3. Department of Radiation Oncology, Sabzevar University of Medical Sciences, Sabzevar, Iran

4. Department of Internal Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran

5. Cancer Research Center, Babol University of Medical Sciences, Babol, Iran

6. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

7. Neyshabur University of Medical Sciences, Neyshabur, Iran

8. Fred Hutchinson Cancer Research Center, The University of Washington, Seattle, WA, USA

9. Department of Radiation Oncology, Edward Hines Jr VA Hospital and Loyola University Chicago Stritch School of Medicine, Chicago, IL, USA

10. Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran

11. Radiation Oncologist, Neyshabur University of Medical Sciences, Neyshabur, Iran

Funder

Sabzevar University of Medical Sciences

Shahid Beheshti University of Medical Sciences

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07357907.2021.1995742

Reference33 articles.

1. The COVID-19 Outbreak in Iran; The First Patient with a Definite Diagnosis

2. COVID-19 Management in Iran as One of the Most Affected Countries in the World: Advantages and Weaknesses

3. Challenges of COVID-19 Vaccination in Iran: In the Fourth Wave of Pandemic Spread

4. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population;International Journal of Immunopathology and Pharmacology;2024-01

2. SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study;Frontiers in Medicine;2023-01-10

3. Antigen rapid diagnostic test monitoring for SARS‐CoV ‐2 in asymptomatic and fully vaccinated cancer patients: Is it cost‐effective?;Cancer Medicine;2022-12-30

4. A year of experience with COVID ‐19 in patients with cancer: A nationwide study;Cancer Reports;2022-11-27

5. Perception and safety analysis of COVID‐19 vaccination in cancer patients: A multicenter, real‐world study;Cancer Medicine;2022-11-13